---
type: "Symbol"
title: "Newamsterdam Pharma - CW27 (NAMSW.US) — Community Discussions"
description: "Community discussions about this stock, including analyst opinions, earnings analysis, and investment strategies from verified financial professionals and active investors."
locale: "en"
url: "https://longbridge.com/en/quote/NAMSW.US/topics.md"
symbol: "NAMSW.US"
parent: "https://longbridge.com/en/quote/NAMSW.US.md"
count: 1
datetime: "2026-03-14T17:21:13.240Z"
locales:
  - [en](https://longbridge.com/en/quote/NAMSW.US/topics.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/NAMSW.US/topics.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/NAMSW.US/topics.md)
---

# Newamsterdam Pharma - CW27 (NAMSW.US) — Community Discussions

### [The Lancet: Phase III clinical trial shows obicetrapib combined with ezetimibe is safe and effective in lowering cholesterol.](https://longbridge.com/en/topics/29596329.md)

- Author: [济无咎](https://longbridge.com/en/profiles/9874868.md)
- Datetime: 2025-05-13T16:04:56.000Z
- Comments: 0
- Obicetrapib is jointly developed by multiple companies, including $Amgen(AMGN.US) and Mitsubishi Tanabe Pharma, and is currently mainly developed and researched by $Newamsterdam Pharma(NAMS.US). Ezeti

## References

- [Newamsterdam Pharma - CW27 (NAMSW.US)](https://longbridge.com/en/quote/NAMSW.US.md)


> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/NAMSW.US/topics.md) | [繁體中文](https://longbridge.com/zh-HK/quote/NAMSW.US/topics.md)